Cell Therapeutics, Inc. ("CTI") announced today that it has received notice that the European Medicines Agency ("EMEA") has validated the expanded Pe...
Cell Therapeutics, Inc. ("CTI" or the "Company") today reported recent accomplishments and financial results for the second quarter ended June 30, 20...
Cell Therapeutics, Inc. ("CTI") today announced it has filed for a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration (&q...
On Thursday, August 5, 2010, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s management team will host a co...
Cell Therapeutics, Inc. (the "Company") today announced the successful closing of its previously announced sale of $4.06 million of securities to an accredited...
Cell Therapeutics, Inc. (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, $4.06 million o...
Cell Therapeutics ("CTI") today announced that it has signed a manufacturing agreement with NerPharMa DS (a pharmaceutical manufacturing company belonging to N...
The IBTAnnouncement Service helps investors discover the latest information reported by companies in which they are invested, including changes in voting rights, net asset values, and more.